Back to search results

Growth Hormone and Beta-cells Study

This research study at the University of Missouri is looking for volunteers to help understand how growth hormone affects beta-cells (cells in your pancreas that make insulin and help control blood sugar). We want to learn more about how growth hormone influences these cells in people who have impaired fasting glucose or impaired glucose tolerance (also known as prediabetes), which are risk factors for developing type 2 diabetes. The study will measure how well your beta-cells are working before and 7 days after receiving rhGH (recombinant human growth hormone). We are looking for people aged 18 to 59 with a BMI between 18.5 and 45.9, and who have impaired fasting glucose or impaired glucose tolerance. This is an observational study, and the current status is unclear.

Study design
This is an observational study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Beta-cell function will be measured before and 7 days after rhGH administration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07581860

Growth Hormone Resistance of Beta-cells

Not Yet Recruiting
Not specifiedAges 18–59Observational
University of Missouri-Columbia
~10 participants
Updated 2026-08-06 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Beta-cell function
Measured over before and 7 days after rhGH administration

Conditions

Healthy
Obesity & Overweight
Impaired Fasting Glucose (IFG)
Impaired Glucose Tolerance (Prediabetes)

Explore related trials

Glucose IntoleranceImpaired fasting glycemiaObesityOverweight

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Bettina Mittendorfer · PRINCIPAL_INVESTIGATOR · University of Missouri-Columbia

Who to contact

Study Coordinator
[email protected]
573-884-6852
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

body mass index \>18.5kg/m2 and \<45.9kg/m2
impaired fasting glucose \>/= 100mg/dL, \</= 126mg/dL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg/dL at two-hours)

Exclusion

pregnant, planning to become pregnant during the study, or breastfeeding
current diagnosis or history of type 1 or type 2 diabetes
use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
history of bariatric surgery
known, uncontrolled hypothyroidism
history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
current cancer or cancer that has been in remission less than 5 years
first degree relative with type 1 diabetes
evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
greater than 3% weight loss within three months of screening or engaged in regular (\>/= 3 days per week), continuous moderate- or high-intensity exercise of \>/= 30 min duration
mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

What this trial measures

  • Beta-cell functionbefore and 7 days after rhGH administration

    Insulin secretion rate in relationship to plasma glucose